[4-(4-Nitrophenyl)but-3-ynyl]carbamic acid tert-butyl ester | 742102-25-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(4-Nitrophenyl)but-3-ynyl]carbamic acid tert-butyl ester
• 英文别名: tert-butyl N-[4-(4-nitrophenyl)but-3-ynyl]carbamate
• CAS: 742102-25-6
• 化学式: C₁₅H₁₈N₂O₄
• 分子量: 290.319
• InChiKey: NVGDAOHXQHHNGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  [4-(4-Nitrophenyl)but-3-ynyl]carbamic acid tert-butyl ester 在 钯 氩 、 氧气 、 氢气 、 氮 、 乙醇 、 silica gel 、 乙酸乙酯 、 hexanes 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以to afford 1.75 g (96%) of the product 52 as a colorless viscous oil的产率得到[4-(4-aminophenyl)butyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Sodium channel blockers

  摘要：

  本发明涉及钠通道阻滞剂。本发明还包括使用这些创新的钠通道阻滞剂的各种治疗方法。

  公开号：

  US06995160B2
• 作为产物：
  描述：

  4-硝基碘苯 、 N-BOC-丁氰-4-胺 在 碘化亚铜 、 双三苯基磷二氯化钯 氩 、 二氯甲烷 、 乙酸乙酯 、 hexanes 作用下， 以 三乙胺 为溶剂， 反应 16.25h， 以to afford 2.08 g (89%) of the product 51 as an orange solid的产率得到[4-(4-Nitrophenyl)but-3-ynyl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Sodium channel blockers

  摘要：

  本发明涉及钠通道阻滞剂。本发明还包括使用这些创新的钠通道阻滞剂的各种治疗方法。

  公开号：

  US20040162296A1

文献信息

• Simultaneous Generation and Subsequent Cycloaddition of <i>ortho</i> -Quinonemethides and Cyclic Enecarbamates Promoted by a Gold/Lewis Acid Catalytic System
  作者：Patricia Fernández、Pedro Alonso、Francisco J. Fañanás、Félix Rodríguez

  DOI：10.1002/ejoc.201800679

  日期：2018.8.7

  A gold/BF3 catalytic system promotes the transformation of simple 3‐butynamines and 2‐(hydroxymethyl)phenol derivatives into cyclic enamines and ortho‐quinone methide derivatives. The subsequent formal [4+2]‐cyclization reaction between these two intermediates gives rise to hexahydrochromeno[2,3‐b]pyrrole derivatives.

  金/ BF 3催化体系促进简单的3-丁炔胺和2-（羟甲基）苯酚衍生物转化为环烯胺和邻醌甲基化物衍生物。这两个中间体之间随后的正式的[4 + 2]-环化反应产生了六氢色素[2,3- b ]吡咯衍生物。
• Hetero substitued sodium channel blockers
  申请人：Johnson R. Michael

  公开号：US20060142581A1

  公开（公告）日：2006-06-29

  The present invention relates to novel pyrazinoylguanidine compounds and methods of using the same.

  本发明涉及新型吡嗪酰基胍化合物及其使用方法。
• SODIUM CHANNEL BLOCKERS
  申请人：JOHNSON R. Michael

  公开号：US20080076782A1

  公开（公告）日：2008-03-27

  The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

  本发明涉及钠通道阻滞剂。本发明还包括使用这些创新的钠通道阻滞剂的各种治疗方法。
• Hetero substituted sodium channel blockers
  申请人：Parion Sciences, Inc.

  公开号：US07875619B2

  公开（公告）日：2011-01-25

  The present invention relates to group of butylphenyl-pyrazinoylguanidine compounds useful as sodium channel blockers. The compounds may be used to promote promoting hydration of mucosal surfaces.

  本发明涉及一组丁基苯基吡嗪酰胍化合物，可用作钠通道阻滞剂。这些化合物可用于促进黏膜表面的水合作用。
• Design, Synthesis, and Structure−Activity Relationships of Novel 2-Substituted Pyrazinoylguanidine Epithelial Sodium Channel Blockers:  Drugs for Cystic Fibrosis and Chronic Bronchitis
  作者：Andrew J. Hirsh、Bruce F. Molino、Jianzhong Zhang、Nadezhda Astakhova、William B. Geiss、Bruce J. Sargent、Brian D. Swenson、Alexander Usyatinsky、Michael J. Wyle、Richard C. Boucher、Rick T. Smith、Andra Zamurs、M. Ross Johnson

  DOI：10.1021/jm051134w

  日期：2006.7.1

  Amiloride (1), the prototypical epithelial sodium channel (ENaC) blocker, has been administered with limited success as aerosol therapy for improving pulmonary function in patients with the genetic disorder cystic fibrosis. This study was conducted to synthesize and identify more potent, less reversible ENaC blockers, targeted for aerosol therapy and possessing minimal systemic renal activity. A series of novel 2-substituted acylguanidine analogues of amiloride were synthesized and evaluated for potency and reversibility on bronchial ENaC. All compounds tested were more potent and less reversible at blocking sodium-dependent shortcircuit current than amiloride. Compounds 30-34 showed the greatest potency on ENaC with IC50 values below 10 nM. A regioselective difference in potency was found (compounds 30, 39, and 40), whereas no stereospecific (compounds 33, 34) difference in potency on ENaC was displayed. Lead compound 32 was 102-fold more potent and 5-fold less reversible than amiloride and displayed the lowest IC50 value ever reported for an ENaC blocker.